Fact based stock research
Zhejiang Hisun Pharmaceutical (SHSE:600267)


Zhejiang Hisun Pharmaceutical stock research in summary

hisunpharm.com


Zhejiang Hisun Pharmaceutical shares have a BUY rating. While they are good value, they are riskily financed, and show below average growth. We recommend buying and holding Zhejiang Hisun Pharmaceutical shares.


Latest Obermatt Ranks


Country China
Industry Pharmaceuticals
Index SSE Composite
Size class Medium

June 8, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Research History: Zhejiang Hisun Pharmaceutical

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
78
58
60
65
STOCK GROWTH RANKS
16
39
100
40
STOCK SAFETY RANKS
26
36
25
42
COMBINED STOCK RANKS
25
33
33
100

Last update of Combined Rank: 8-Jun-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Zhejiang Hisun Pharmaceutical in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 8-Jun-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Zhejiang Hisun Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
23
46
72
33
PROFIT GROWTH
64
64
64
50
STOCK RETURNS
20
43
51
77
CONSOLIDATED RANK: GROWTH
16
39
100
40

Financial reporting date of Growth Rank: 31-Mar-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Zhejiang Hisun Pharmaceutical.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
4
6
6
6
REFINANCING
88
90
77
82
LIQUIDITY
20
24
55
42
CONSOLIDATED RANK: SAFETY
26
36
25
42

Financial reporting date of Safety Rank: 31-Mar-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Zhejiang Hisun Pharmaceutical and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Zhejiang Hisun Pharmaceutical from June 8, 2018.